Inovio Pharmaceuticals (INO) Long-Term Deferred Tax (2011 - 2015)

Inovio Pharmaceuticals has reported Long-Term Deferred Tax for 5 years, with the latest figure at $6.1 million in Q4 2015.

• Quarterly Long-Term Deferred Tax rose 95.62% year-over-year to $6.1 million in Q4 2015, while the trailing twelve-month figure through Dec 2015 was $6.1 million (up 95.62% YoY) and the FY2015 annual result came in at $6.1 million, up 95.62% from the prior year.
• Long-Term Deferred Tax advanced to $6.1 million in Q4 2015 per INO's latest filing, from $3.1 million in the prior quarter.
• Over five years, Long-Term Deferred Tax peaked at $6.1 million in Q4 2015 and troughed at $1.1 million in Q4 2013.
• A 5-year average of $2.8 million and a median of $1.9 million in 2012 frame the typical range for Long-Term Deferred Tax.
• The sharpest annual moves came in 2013 and 2014: Long-Term Deferred Tax plunged 44.13% in 2013, then jumped 188.29% in 2014.
• Over 5 years, Long-Term Deferred Tax stood at $1.8 million in 2011, then advanced by 5.89% to $1.9 million in 2012, then slumped by 44.13% to $1.1 million in 2013, then surged by 188.29% to $3.1 million in 2014, then jumped by 95.62% to $6.1 million in 2015.
• According to Business Quant data, Long-Term Deferred Tax over the past three periods registered $6.1 million, $3.1 million, and $1.1 million for Q4 2015, Q4 2014, and Q4 2013 respectively.